We take advantage of the versatility of RNAi, used to down-regulate the expression of target genes in specific hand-picked gene sequences, and aim at any and all regions, both structural and functional, where essential, pathogenic, or resistance genes are present.
All the action happens simultaneously, like a shotgun.

True to EVs’ natural role as primary communication channel between cells, we engineered our microalgae-based EVs (MEVs) to serve as Drug Delivery System (DDS), to carry, protect, and deliver their cargo right into human or bacterial cells. By design, MEVs can be either generic (targeting a variety of tissues and allowing for multiple administration routes) or specific.

Microalgae are free from human pathogens (e.g. viruses, mycoplasma), and their MEVs are non-toxic as well as non-immunogenic for humans. Unlike most of the current pharmaceutical industry, which uses animal cells or synthetic biology for the manufacturing of proteins, viral vectors, and EVs among others, our technology offers a safer alternative.

Requiring only light, water, and salts, microalgae-based biologics are produced and purified using inherently clean and simple processes, with low-to-no media supplements, that can easily be scaled-up in compliance with cGMP regulations. Equipped with cutting-edge Photo-Bioreactors (PBRs) and industry-standard Downstream Processing (DSP) tools, we achieve a high-yield, low-cost overall process.